Uncategorized

Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B

Published

1 week ago

on

For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version